AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.
Here is a selection of people starting new roles with Waterways Ireland, IOB, Eaton, AbbVie Ireland, Deloitte Ireland and ...
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
AbbVie is eligible to receive tiered royalties on net sales ... PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and ...
Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...